Escend Pharmaceuticals, Inc., is developing therapeutics for cancer orphan indications. Our development focus includes therapeutics that kill cancer stem cells in chronic myelogenous leukemia and related hematologic malignancies.

Our proprietary process is based on new scientific discoveries about mechanisms of action of drug candidates and the effects of second messenger systems on cellular pathways that are shared in multiple disease indications.

Our proprietary process is based on new scientific discoveries about mechanisms of action of drug candidates and the effects of second messenger systems on cellular pathways that are shared in multiple disease indications.

  • Escend has created a process to accelerate drug discovery which utilizes integrative biological approaches and risk reduction strategies to identify common cellular pathways among multiple diseases.

  • We select small molecule drug candidates with established safety profiles that have not yet achieved US marketing approval. We match these agents based on recent scientific evidence with disease indications, where their effects on specific cellular pathways can be exploited for the development of novel therapeutics.

  • These candidates are optimized utilizing applied medicinal chemistry to create new analogs to maximize their therapeutic effects for diseases with high unmet medical needs.